Pharmacotherapy for children and adolescents with epilepsy

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 175-194

  Verrotti, Alberto ^a   Loiacono, Giulia ^a   Coppola, Giangennaro ^b   Spalice, Alberto ^c   Mohn, Angelika ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiepileptic drugs; Childhood epilepsy; Efficacy; Treatment of epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ACTION POTENTIAL; ACUTE HEMORRHAGIC PANCREATITIS; ADJUVANT THERAPY; AGGRESSION; ALOPECIA; ANOREXIA; ANTICONVULSANT THERAPY; ANXIETY DISORDER; APLASTIC ANEMIA; APPETITE; ASTHENIA; ATAXIA; AUTOMUTILATION; BEHAVIOR DISORDER; BENIGN CHILDHOOD EPILEPSY; BLOOD CLOTTING; BLURRED VISION; BODY WEIGHT; BONE DEFECT; BRAIN DISEASE; CEREBELLUM ATROPHY; CLONIC SEIZURE; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; CONSTIPATION; DATA BASE; DEPERSONALIZATION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPILEPSY; EPILEPTIC STATE; EUPHORIA; EXFOLIATIVE DERMATITIS; FACE EDEMA; FATIGUE; FOCAL EPILEPSY; GAIT; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HEADACHE; HICCUP; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERANDROGENISM; HYPERTHERMIA; HYPOCALCEMIA; HYPONATREMIA; INFANTILE SPASM; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; LIVER METABOLISM; LIVER TOXICITY; MEDLINE; MENTAL INSTABILITY; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NAUSEA; NERVOUSNESS; NEUROTOXICITY; OSTEOMALACIA; OVARY POLYCYSTIC DISEASE; PSYCHOSIS; RASH; RECOMMENDED DRUG DOSE; RETT SYNDROME; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STUPOR; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TONIC CLONIC SEIZURE; TONIC SEIZURE; TREMOR; VISUAL FIELD DEFECT; VOMITING; WEIGHT REDUCTION; WEST SYNDROME; WITHDRAWAL SYNDROME;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS;

EID: 78651449242     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.517194     Document Type: Review

References (176)

1. Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Health Technol Assess 2006;10(7):118
2. Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin Pediatr Neurol 1997;4:9-18 (Pubitemid 27137470)
3. Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother 2007;7:179-93
4. Lerman P, Kivity-Ephraim S. Carbamazepine efficacy and utilization in children. Epilepsia 1974;15:229-34
5. Levy RH, Mattson RH, Meldrum BS, Perucca E. Antiepileptic drugs. 5th edition. Lippincott Williams & Wilkins; 1992
6. Zimmermann FT, Burgmeister BB. A new drug for petit mal epilepsy. Neurology 1958;8:769-75
7. Capovilla G, Beccaria F, Veggiotti P, et al. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999;14:395-400 (Pubitemid 29321100)
8. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161
9. Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Ann Neurol 1980;7:583-4
10. Mattson R, Ccramer J, Collins J, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51 (Pubitemid 15047456)
11. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures - effects on intelligence and on seizure recurrence. N Engl J Med 1990;322:364-9
12. Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Pediatr Neurol 1996;14:36-40 (Pubitemid 26069529)
13. Vining EPG, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-74
14. Banu SH, Jahan M, Koli UK, et al. Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007;334:1207 (Pubitemid 46954585)
15. Pal DK, Das T, Chaudhury G, et al. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23 (Pubitemid 28020161)
16. Hahn TJ. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 1975;292:550
17. Mitchell W, Chavez J. Carbamazepine versus Phenobarbital for partial onset seizures in children. Epilepsia 1987;28:56-60 (Pubitemid 17231447)
18. Perucca E. In: Levy RH, Mattson RH, Meldrum BS, editors, Antiepileptic drugs. 5th edition. Lippincott Williams & Wilkins; 2002
19. Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938;11:1068-73
20. Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 1986;20:171-84 (Pubitemid 16044204)
21. Anast CS. Anticonvulsant drugs and calcium metabolism. N Engl J Med 1975;292:587-8
22. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990;40:456-60
23. Verrotti A, Coppola G, Parisi P, et al. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010;112:1-10
24. Bryant A, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996;46:465-9
25. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993;4:177-83
26. Verrotti A, DEgidio C, Coppola G, et al. Epilepsy, sex hormones and antiepileptic drugs in female patients. Expert Rev Neurother 2009;9(12):1803-14
27. Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate. Dev Med Child Neurol 1977;19:9-25
28. Ramsay RE, Wilder BJ, Murphy JV, et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. J Epilepsy 1992;5:55-60
29. Spitz MC, Deasy DN. Conversion to valproate monotherapy in nonretarded adults with primary generalized tonic-clonic seizures. J Epilepsy 1991;4:33-8
30. Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986;8:47-52 (Pubitemid 16080207)
31. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720 (Pubitemid 13184215)
32. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(Suppl 2):S8-Sll (Pubitemid 18035481)
33. Barnes SE, Bower BD. Sodium valproate in the treatment of intractable childhood epilepsy. Dev Med Child Neurol 1975;17:175-81
34. Yokoyama S, Kodama S, Ogini H. Study of the treatment of infantile spasms. Brain Dev 1976;8:447-53
35. Brachet-Liermain A, Demarquez JL. Pharmacokinetics of dipropylacetate in infants and young children. Pharm Week 1977;112:293-7
36. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26 (Pubitemid 46436124)
37. Graves NM, Leppik IE. Advances in pharmacotherapy: recent developments in the treatment of epilepsy. J Clin Pharm Ther 1993;18:227-42
38. Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003;3:CD003277
39. Brodie MJ. Felbamate: a new antiepileptic drug. Lancet 1993;341:1445-6
40. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;4(5):S2-10
41. Sanka R, Holmes GL. Mechanisms of action for the commonly-used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects. J Child Neurol 2004;19(Suppl 1):S6-14
42. Sachdeo R, Narang-Sachdeo SK, Shumaker RC, et al. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1200-6000 mg/day in subjects with epilepsy. Epilepsia 1997;38:887-92 (Pubitemid 27323597)
43. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit 1997;19(1):29-36 (Pubitemid 28068991)
44. Anonymous. Recommendation for the immediate withdrawal of patients from treatment with Felbatol(R) (felbamate). FDA Med Bull (1994);24(2):5.
45. Pellock JM, Brodie MJ. Felbamate: update. Epilepsia 1997;38(12):1261-4
46. Jarrar RG, Buchhalter JR. Therapeutics in pediatric epilepsy, Part 1: the new antiepileptic drugs and the ketogenic diet. Mayo Clin Proc 2003;78:359-70
47. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328(1):29-33
48. Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999;34(2-3):91-7 (Pubitemid 29155479)
49. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures:an active-control trial. Neurology 1994;43:688-92 (Pubitemid 23121957)
50. Zupanc ML, Werner R, Arentz L. Efficacy of felbamate in the treatment of medically refractory epilepsy in children [abstract]. Epilepsia 2003;44:273
51. Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001;47(1-2):1-7 (Pubitemid 32973642)
52. Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995;10(2):134-6
53. Devinsky O, Kothari M, Rubin R, et al. Felbamate for absence seizures [abstract]. Epilepsia 1992;33(Suppl 3):84
54. Grosso S, Cordelli DM, Coppola G, et al. Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 2008;15:940-6
55. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994;28:1188-96
56. Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-5
57. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in na?ve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11:470-5 (Pubitemid 26412201)
58. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures; a 12-week, multicentre, double-blind placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999;40(8):1147-54 (Pubitemid 29372632)
59. Khurana DS, Riviello J, Helmers S, et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128(6):829-33 (Pubitemid 26181381)
60. Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000;38:27-32 (Pubitemid 30055313)
61. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-120 (Pubitemid 44086745)
62. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20:S1-56 (Pubitemid 41131320)
63. McDonald DG, Najam Y, Keegan MB, et al. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure 2005;14(2):112-16 (Pubitemid 40214737)
64. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000;23:160-3
65. Culy CR, Goa KL. Lamotriginre. A review of its use in childhood epilepsy. Pediatr Drugs 2000;2:299-330 (Pubitemid 30636013)
66. Guberman AH, Besag FMC, Brodie MJ, et al. Lamotrigine-associated rash: risk/ benefit considerations in adults and children. Epilepsia 1999;40:985-91
67. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33(10):1037-42
68. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12 (Pubitemid 28006785)
69. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51 (Pubitemid 126687054)
70. Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994;344:1375-6
71. Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995;91:200-2
72. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 1993;24:339-40 (Pubitemid 24009798)
73. Nieto-Barrera M, Brozmanova M, Capovilla G, et al.; Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46(2):145-55
74. Coppola G, Auriechio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an openlabel, randomized, parallel-group study. Epilepsia 2004;45(9):1049-53 (Pubitemid 39238114)
75. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9 (Pubitemid 29316053)
76. Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65(11):1737-43 (Pubitemid 43754402)
77. Duchowny M, Gilman J, Messenheimer J, et al.; LAMICTAL Pediatric Study Group. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol 2002;17(4):278-85 (Pubitemid 34823425)
78. Welty TE, Gidal BE, Ficker DM, Privitera MD. LEV: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 2002;36:296-304
79. Lynch BA, Lambeng N, Nocka F, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug LEV. Proc Natl Acad Sci USA 2004;101:9861-6 (Pubitemid 38869327)
80. Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007;48:1861-9 (Pubitemid 47537431)
81. Carunchio I, Pieri M, Ciotti MT, et al. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug LEV. Epilepsia 2007;48:654-62 (Pubitemid 46587620)
82. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA and glycine-gated currents. Br J Pharmacol 2002;136:659-72 (Pubitemid 34785708)
83. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18 (Pubitemid 34215447)
84. French J. Use of levetiracetam in special populations. Epilepsia 2001;42(Suppl 4):40-3 (Pubitemid 32802087)
85. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002;43:518-24
86. Vigevano F. Levetiracetam in pediatrics. J Child Neurol 2005;20:87-93 (Pubitemid 40484845)
87. Chung AM, Eiland LS. Use of second-generation antiepileptic drugs in the pediatric population. Pediatr Drugs 2008;10(4):217-54 (Pubitemid 351920117)
88. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8 (Pubitemid 46208740)
89. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60. (Pubitemid 350059304)
90. Di Bonaventura C, Fattouch J, Mari F, et al. Clinical experience with LEV in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005;7:231-5 (Pubitemid 41392423)
91. Andermann E, Andermann F, Meyvish P, Tonner F. Efficacy and tolerability LEV add-on therapy in patients with refractory idiopathic generalised epilepsy. Epilepsia 2006;47:187
92. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebocontrolled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-60 (Pubitemid 43964617)
93. Wheless JW, Ng YT. LEV in refractory pediatric epilepsy. J Child Neurol 2002;17:413-15
94. Lagae L, Buyes G, Ceulemans B. Clinical experience with LEV in childhood epilepsy: an add-on and monotherapy trial. Seizures 2005;14:66-71 (Pubitemid 40103960)
95. Verrotti A, Coppola G, Manco R, et al. LEV monotherapy for children and adolescentes with benign rolandic seizures. Seizure 2007;16:271-5 (Pubitemid 46336818)
96. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16 (Pubitemid 351294638)
97. Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure 2003;12:157-9 (Pubitemid 36443009)
98. Garcia C, Rubio G. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. Epilepsy Res 2009;85:318-20
99. Verrotti A, Parisi P, Loiacono G, et al. Levetiracetam monotherapy for childhood occipital epilepsy of gastaut. Acta Neurol Scand 2009;120:342-6
100. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4 (Pubitemid 47205686)
101. Papacostas S, Kkolou E, Papathanasiou E. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007;29:164-6 (Pubitemid 46872975)
102. De Los Reyes EC, Sharp GB, Williams JP, et al. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30:54-6
103. Lawlor KM, Devlin AM. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005;9:19-22
104. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004;13:475-7
105. Sharpe DV, Patel AD, Abou-Khalil B, et al. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure 2008;17:64-8 (Pubitemid 350257002)
106. Wheless JW. Levetiracetam in the treatment of childhood epilepsy. Neuropsychiatr Dis Treat 2007;3(4):409-21
107. Lee YJ, Kang HC, Kim HD, Lee JS. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. Pediatr Neurol 2010;42(2):86-92
108. Li S, Cao J, Xiao N, Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol 2010;25(5):609-13
109. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:1-4 (Pubitemid 29130316)
110. Phelps SJ, Wheless JW. Oxcarbazepine: a brief review. J Pediatr Pharmacol Ther 2005;10:248-53
111. Tecoma ES. Oxcarbazepine. Epilepsia 1999;40(Suppl 5):S37-46
112. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45:410-23 (Pubitemid 38581554)
113. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001;132:1-4 (Pubitemid 32128426)
114. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93
115. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13 (Pubitemid 43919479)
116. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, doubleblind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45(1):20-7 (Pubitemid 38063660)
117. Beydoun A, Uthman BM, Kugler AR, et al.; Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64(3):475-80
118. Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005;46(12):1926-36 (Pubitemid 44922003)
119. French JA, Kugler AR, Robbins JL, et al. Doseresponse trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60(10):1631-7 (Pubitemid 36618090)
120. Jan MMS, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009;40:347-50
121. Brunner LA, Harrigan EP, John VA, Powell ML. Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400-1200 mg. Am J Ther 1994;1:215-20
122. Arroyo S. Rufinamide. Neurotherapeutics 2007;4(1):155-62 (Pubitemid 46107325)
123. Arroyo S, Sachdeo R, Rosenfeld W, et al. Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures [abstract]. Epilepsia 2005;46(Suppl 8):193
124. Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010;10:1-6
125. Wheless J, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of seven clinical trials. J Child Neurol 2009;50:1158-66
126. Brodie MJ, Rosenfeld W, Vazquez B, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures [abstract]. Neurology 2006;66(Suppl 2):A35-6
127. Elger C, Stefan H, Perdomo C, Arroyo S. Dose-response relationships of rufinamide in patients with inadequately controlled partial seizures [abstract]. Neurology 2006;66(Suppl 2):A37-8
128. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899-909
129. Todorov A, Biton V, Krauss GL, et al. Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia 2005;46(Suppl 8):218-19
130. Elger CE, Stefan H, Mann A, et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-63
131. Glauser T, Kluger G, Sachdeo R, et al. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut Syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology 2005;64(Suppl 1):1826
132. Glauser T, Kluger G, Sachdeo R, et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia 2005;46(Suppl 6):408.
133. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-5
134. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999;40(Suppl 9):S7-13
135. Ettinger AB, Bernal OG, Andriola MR, et al. Two cases of nonconvulsive status epilepticus in association with TGB therapy. Epilepsia 1999;40:1159-62
136. Pereira J, Marson AG, Hutton JL. TGB add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(3):CD001908
137. Uldall P, Bulteau C, Pederson A, et al. TGB adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000;42:159-68
138. Koepp MJ, Edwards M, Collins J, et al. Status epilepticus and TGB therapy revisited. Epilpesia 2005;46:1625-32 (Pubitemid 44921937)
139. Ben-Menachem E. International experience with TGB add-on therapy. Epilepsia 1995;36:S14-21 (Pubitemid 26106917)
140. Boellner SW, McCarty J, Mercante D, et al. Pilot study of TGB in children with partial seizures [abstract]. Epilepsia 1996;37:S92-41
141. Boellner SW, Deaton R, Sommerville KW. Long-term treatment of partial seizures with TGB in ehildren [abstact]. Epilepsia 1997;38:S208
142. Al-jayyousi M, Helmers SL. TGB in the treatment of infantile spasms [abstract]. Epilepsia 1998;39:166
143. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15:S22-6
144. Grosso S, Galimberti D, Fametani MA, et al. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005;14:183-9 (Pubitemid 40425267)
145. Glauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000;41:S86-90-25 (Pubitemid 30202349)
146. Glauser TA, Clark PO, MeGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41:S91-4 (Pubitemid 30202350)
147. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-77 (Pubitemid 34774257)
148. Arcas J, Ferrer T, Roche MC, Martinez A. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42(10):1363-5 (Pubitemid 33070679)
149. Biton V, Bourgeois BF. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005;62:1705-8 (Pubitemid 41626666)
150. Menachem EB, Sander JW, Stefan H, et al. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther 2008;30(7):1180-95
151. Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008;(3):CD001417.
152. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:1338-44 (Pubitemid 29190521)
153. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313(7066):1169-74
154. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314(7075):180-1 (Pubitemid 27037871)
155. Willmore LJ, Abelson MB, Menachem EB, et al. Vigabatrin: 2008 Update. Epilepsia 2009;50(2):163-73 (Pubitemid 44606279)
156. Kellermann K, Soditt V, Rambeck B, et al. Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurol Scand 1996;93:380-1 (Pubitemid 26201469)
157. Uldall P, Alving J, Gram L, Hogenhaven H. Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 1995;26:253-6
158. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;(Suppl 2):S52-9
159. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-21 (Pubitemid 32995722)
160. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-8 (Pubitemid 39488062)
161. Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ 2000;320:1404-5
162. Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol 2004;19:401-4 (Pubitemid 39232330)
163. Gobbi G, Pini A, Bertani G, et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 1999;35:29-37 (Pubitemid 29191492)
164. Ohtahara S. Zonisamide in the management of epilepsy-Japanese experience. Epilepsy Res 2006;68(Suppl 2):S25-33
165. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31-41 (Pubitemid 40179930)
166. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347-67 (Pubitemid 40593608)
167. Low PA, James S, Peschel T, et al. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res 2004;62:27-34 (Pubitemid 39424188)
168. Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008;12(1):19-23 (Pubitemid 350258688)
169. Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83(2-3):112-16
170. Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006;34(5):351-4
171. Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77-80 (Pubitemid 40138686)
172. Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004;62(2):296-8.
173. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6(4):267-70 (Pubitemid 40095991)
174. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;64(1-2):31-4 (Pubitemid 40726163)
175. You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;30(4):287-90
176. Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010;19(1):31-5.